3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Multiple Myeloma
4
Smoldering Multiple Myeloma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Leukemia, Promyelocytic, Acute
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Filgrastim
18
Cyclophosphamide
13
Etoposide
12
Peripheral Blood Stem Cell Transplantation
11
Ifosfamide
11
Vincristine
9
Carboplatin
9
Radiotherapy
8
Doxorubicin
8
Melphalan
7
Topotecan
6
Temozolomide
5
Granulocyte Colony-Stimulating Factor
5
Busulfan
5
Thiotepa
4
Irinotecan
4
Docetaxel
4
trioctyl phosphine oxide
3
cixutumumab
3
Imatinib Mesylate
3
Amifostine
3
tanespimycin
2
pegfilgrastim
2
ixabepilone
2
etoposide phosphate
2
Oxaliplatin
2
Neoadjuvant Therapy
2
Microarray Analysis
2
Mesna
2
Magnetic Resonance Spectroscopy
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Neuroectodermal Tumors, Primitive, Peripheral
×
Maintenance
×
Clear all
NCT03011528
2025-11-21
CombinaiR3
Institut Curie
Phase 2
Completed
45 enrolled